Page 1831 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 106 Haploidentical Hematopoietic Cell Transplantation 1632.e1

REFERENCES 23. Martin AM, Kulski JK, Witt C, et al: Leukocyte Ig-like receptor
complex (LRC) in mice and men. Trends Immunol 23(2):81–88, 2002.
1. Gragert L, Eapen M, Williams E, et al: HLA match likelihoods for 24. Shilling HG, Guethlein LA, Cheng NW, et al: Allelic polymorphism
hematopoietic stem-cell grafts in the U.S. registry. N Engl J Med synergizes with variable gene content to individualize human KIR
371(4):339–348, 2014. genotype. J Immunol 168(5):2307–2315, 2002.
2. Kanda Y, Chiba S, Hirai H, et al: Allogeneic hematopoietic stem cell 25. Valiante NM, Uhrberg M, Shilling HG, et al: Functionally and struc-
transplantation from family members other than HLA-identical siblings turally distinct NK cell receptor repertoires in the peripheral blood of
over the last decade (1991-2000). Blood 102(4):1541–1547, 2003. two human donors. Immunity 7:739, 1997.
3. Wang Y, Liu DH, Xu LP, et al: Superior graft-versus-leukemia effect 26. Kim S, Poursine-Laurent J, Truscott SM, et al: Licensing of natural
associated with transplantation of haploidentical compared with HLA- killer cells by host major histocompatibility complex class I molecules.
identical sibling donor grafts for high-risk acute leukemia: an historic Nature 436(7051):709–713, 2005.
comparison. Biol Blood Marrow Transplant 17(6):821–830, 2011. 27. Yokoyama WM, Kim S: Licensing of natural killer cells by self-major
4. Suchin EJ, Langmuir PB, Palmer E, et al: Quantifying the frequency of histocompatibility complex class I. Immunol Rev 214(1):143–154,
alloreactive T cells in vivo: new answers to an old question. J Immunol 2006.
166(2):973–981, 2001. 28. Shifrin N, Raulet DH, Ardolino M: NK cell self tolerance, responsive-
5. Szydlo R, Goldman JM, Klein JP, et al: Results of allogeneic bone ness and missing self recognition. Semin Immunol 26(2):138–144,
marrow transplants for leukemia using donors other than HLA-identical 2014.
siblings. J Clin Oncol 15(5):1767–1777, 1997. 29. Boudreau Jeanette E, Liu XR, et al: Cell-extrinsic MHC class I mol-
6. Ash RC, Horowitz MM, Gale RP, et al: Bone marrow transplantation ecule engagement augments human NK cell education programmed by
from related donors other than HLA-identical siblings: effect of T cell cell-intrinsic MHC class I. Immunity 45(2):280–291, 2016.
depletion. Bone Marrow Transplant 7(6):443–452, 1991. 30. Orr MT, Murphy WJ, Lanier LL: Unlicensed’ natural killer cells
7. Melenhorst JJ, Scheinberg P, Williams A, et al: Alloreactivity across dominate the response to cytomegalovirus infection. Nat Immunol
HLA barriers is mediated by both naïve and antigen-experienced T 11(4):321–327, 2010.
cells. Biol Blood Marrow Transplant 17(6):800–809, 2011. 31. Du J, Lopez-Verges S, Pitcher BN, et al: CALGB 150905 (Alliance):
8. Finberg R, Burakoff SJ, Cantor H, et al: Biological significance of rituximab broadens the antilymphoma response by activating unli-
alloreactivity: T cells stimulated by Sendai virus-coated syngeneic censed NK cells. Cancer Immunol Res 2(9):878–889, 2014.
cells specifically lyse allogeneic target cells. Proc Natl Acad Sci USA 32. Gleimer M, Parham P: Stress management: MHC class I and class
75(10):5145–5149, 1978. I-like molecules as reporters of cellular stress. Immunity 19(4):469–477,
9. Amir AL, D’Orsogna LJA, Roelen DL, et al: Allo-HLA reactivity of 2003.
virus-specific memory T cells is common. Blood 115(15):3146–3157, 33. Gasser S, Orsulic S, Brown EJ, et al: The DNA damage pathway regu-
2010. lates innate immune system ligands of the NKG2D receptor. Nature
10. Westerhuis G, de Witte M, Schumacher TN, et al: Barriers to 436(7054):1186–1190, 2005.
chimerism after major histocompatibility complex-mismatched stem 34. Dokun AO, Kim S, Smith HR, et al: Specific and nonspecific NK cell
cell transplantation: a potential role for heterologous immunity. Exp activation during virus infection. Nat Immunol 2(10):951–956, 2001.
Hematol 42(9):753–760, 2014. 35. Wang LL, Chu DT, Dokun AO, et al: Inducible expression of the gp49B
11. Nadazdin O, Boskovic S, Murakami T, et al: Host alloreactive memory inhibitory receptor on NK cells. J Immunol 164(10):5215–5220, 2000.
T cells influence tolerance to kidney allografts in nonhuman primates. 36. Ruggeri L, Capanni M, Casucci M, et al: Role of natural killer cell
Sci Transl Med 3:86ra51, 2011. alloreactivity in HLA-mismatched hematopoietic stem cell transplanta-
12. Fuchs EJ, Matzinger P: B cells turn off virgin but not memory T cells. tion. Blood 94(1):333–339, 1999.
Science 258:1156–1159, 1992. 37. Ruggeri L, Capanni M, Urbani E, et al: Effectiveness of donor natural
13. Ashwell JD, DeFranco AL, Paul WE, et al: Antigen presentation by killer cell alloreactivity in mismatched hematopoietic transplants.
resting B cells: radiosensitivity of the antigen-presentation function and Science 295:2097, 2002.
two distinct pathways of T cell activation. J Exp Med 159(3):881–905, 38. Ruggeri L, Mancusi A, Capanni M, et al: Donor natural killer cell
1984. allorecognition of missing self in haploidentical hematopoietic trans-
14. Yang J, Brook MO, Carvalho-Gaspar M, et al: Allograft rejection plantation for acute myeloid leukemia: challenging its predictive value.
mediated by memory T cells is resistant to regulation. Proc Natl Acad Blood 110(1):433–440, 2007.
Sci USA 104(50):19954–19959, 2007. 39. Aversa F, Tabilio A, Velardi A, et al: Treatment of high-risk acute
15. Afzali B, Mitchell PJ, Scottà C, et al: Relative resistance of human leukemia with T-cell-depleted stem cells from related donors with one
+
+
+
CD4 memory T cells to suppression by CD4 CD25 regulatory T fully mismatched HLA haplotype. N Engl J Med 339(17):1186–1193,
cells. Am J Transplant 11(8):1734–1742, 2011. 1998.
16. Ayasoufi K, Yu H, Fan R, et al: Pretransplant antithymocyte globulin 40. Aversa F, Terenzi A, Tabilio A, et al: Full haplotype-mismatched hema-
has increased efficacy in controlling donor-reactive memory T cells in topoietic stem-cell transplantation: a phase II study in patients with
mice. Am J Transplant 13(3):589–599, 2013. acute leukemia at high risk of relapse. J Clin Oncol 23(15):3447–3454,
17. Gurkan S, Luan Y, Dhillon N, et al: Immune reconstitution following 2005.
rabbit antithymocyte globulin. Am J Transplant 10(9):2132–2141, 41. Shlomchik WD, Couzens MS, Tang CB, et al: Prevention of graft
2010. versus host disease by inactivation of host antigen- presenting cells.
18. Pearl JP, Parris J, Hale DA, et al: Immunocompetent T-cells with a Science 285(5426):412–415, 1999.
memory-like phenotype are the dominant cell type following antibody- 42. Hsu KC, Gooley T, Malkki M, et al: KIR ligands and prediction of
mediated T-cell depletion. Am J Transplant 5(3):465–474, 2005. relapse after unrelated donor hematopoietic cell transplantation for
19. Gladstone DE, Zachary AA, Fuchs EJ, et al: Partially mismatched hematologic malignancy. Biol Blood Marrow Transplant 12(8):828–836,
transplantation and human leukocyte antigen donor-specific antibod- 2006.
ies. Biol Blood Marrow Transplant 19(4):647–652, 2013. 43. Marmont AM, Horowitz MM, Gale RP, et al: T-cell depletion of
20. Anasetti C, Amos D, Beatty PG, et al: Effect of HLA compatibility on HLA-identical transplants in leukemia. Blood 78(8):2120–2130,
engraftment of bone marrow transplants in patients with leukemia or 1991.
lymphoma. N Engl J Med 320(4):197–204, 1989. 44. Clift RA, Buckner CD, Appelbaum FR, et al: Allogeneic marrow
21. Kärre K, Ljunggren HG, Piontek G, et al: Selective rejection of transplantation in patients with chronic myeloid leukemia in the
H-2-deficient lymphoma variants suggests alternative immune defense chronic phase: a randomized trial of two irradiation regimens. Blood
strategy. Nature 319:675, 1986. 77(8):1660–1665, 1991.
22. Ljunggren HG, Kärre K: In search of the ‘missing self’: MHC molecules 45. Truitt RL, Atasoylu AA: Impact of pretransplant conditioning and donor
and NK cell recognition. Immunol Today 11:237, 1990. T cells on chimerism, graft-versus-host disease, graft-versus-leukemia